Acute Myeloid Leukemia
Results with clinical significance
The presence and pattern of gene mutations in a known or suspected hematologic neoplasm can provide critical diagnostic, prognostic, and therapeutic information for physicians. While many hematologic neoplasms show morphologic or phenotypic similarities, most harbor a distinct composition of somatic gene mutations. In addition, many myeloid neoplasms lack a clonal bone marrow cytogenetic finding at diagnosis (normal karyotype) but can be better characterized with the aid of a sufficiently comprehensive gene mutation profile.
At Mayo Clinic Laboratories, we strive to provide the highest quality molecular services available to complement your clinical practice by offering three myeloid gene panels, including a comprehensive 42-gene OncoHeme panel and two acute myeloid leukemia (AML) focused subpanels
Cost savings comparison to traditional client ordering for MDS
- Historical ordering pattern- Chromosomes and MDS FISH ordered in tandem
- Research has shown FISH is not needed when chromosome results are successful
- Mayo algorithm to hold FISH and cancel when chromosome results are successful
- 70% reduction in unnecessary FISH testing
- 100 MDS patients = Average savings of $49,000
Which test should I order?
Myeloid Blast and Maturation Assessment by Flow Cytometry (“MDS Flow”)
Diagnosis of myelodysplastic syndrome and other myeloid neoplasms requires correlation of clinical, morphologic, and cytogenetic findings, but flow cytometric immunophenotyping method can be useful in assessing myeloid dysmaturation. Dragan Jevremovic, M.D., Ph.D., describes a flow cytometric test to detect aberrant patterns of expression in the diagnosis of myelodysplastic syndrome.
Next-Generation Sequencing for Acute Myeloid Leukemias
Our NGS testing for AML and MDS offers both comprehensive and focused approached to testing. Flexible ordering includes 4-gene, 11-gene, and 42-gene panels to meet your patients’ specific needs, with the option of add-on (reflex) analysis for the additional genes in the 42-gene panel if a smaller panel was ordered initially. The comprehensive 42 genes panel follows World Health Organization and National Comprehensive Cancer Network guidelines for genes of clinical significance – diagnostic, prognostic, therapeutic, or germline our test has your patients covered.
Which test should I order?
Learn more about how to order these evaluations at your institution.
Additional Resources
Next-generation sequencing for myeloid malignancies
David Viswanatha, M.D., gives an overview of the next-generation sequencing (NGS) testing for myeloid malignancies available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.
Webinar - NGS Testing for hematologic maligancies
This "Specialty Testing" webinar offers an educational overview of next-generation sequencing testing for hematologic malignancies, specifically myeloid disorders and multiple myeloma.